Dr. Anjali Pandey is Senior Vice President, Medicinal Chemistry of Sudo Biosciences, where she has led medicinal chemistry since the company’s founding in 2020. Previously, Anjali was head of medicinal chemistry at Lengo Therapeutics (acquired by Blueprint Medicines Dec 2021) from April 2020 – March 2022. At Lengo Therapeutics, she led the discovery of first-in-human Phase 1/2 clinical candidate LNG-451 (BLU-451). Prior to her role at Lengo, Anjali was CSO/EVP for BridgeBio Pharma oncology companies TheRas Inc., Ferro Therapeutics and Navire Pharma. Prior to that, she spent 14 years at Portola Pharmaceuticals as SVP of Medicinal Chemistry & Chemical Development, where she managed discovery and chemistry, manufacturing and controls (CMC) function for Bevyxxa™, Cerdulatinib and all the other small molecule programs.

Anjali has published 45+ scientific publications and is an inventor on over 70 issued U.S. patents. She has been a significant contributor towards the discovery, development and IND-ready and/or 1st in human study for 15 compounds.

Anjali received her M.S. from the Indian Institute of Technology, Kanpur and a Ph.D. from Southern Illinois University.  She completed her postdoctoral fellowship at SRI International.